Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector March 2025: Trump’s FDA overhaul spooks biotech stocks; Roche, AbbVie, Novo ink obesity drug deals

Stock Recap
#PipelineProspector

ONGLYZA

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

20 API Suppliers, 12 USDMF, 8 EU WC, 6 NDC API, 5 Listed Suppliers, $ API Reference Price

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

41 FDF Dossiers, 30 FDA Orange Book, 2 Europe, 9 Canada

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 SPI Pharma, 5 DKSH, 3 Faran Shimi Pharmaceutical, 4 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Aeon Procare, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 1 Clariant, 5 Corel Pharma Chem, 6 DFE Pharma, 7 Gangwal Chemicals, 3 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 26 Kerry, 1 Kima Chemical, 13 Microlex e.U, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 3 Prachin Chemical, 10 Roquette, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 1 The Dow Chemical Company, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

45 Fillers, Diluents & Binders, 23 Coating Systems & Additives, 17 Thickeners and Stabilizers, 15 Disintegrants & Superdisintegrants, 14 Direct Compression, 12 Lubricants & Glidants, 11 Granulation, 8 Co-Processed Excipients, 8 Controlled & Modified Release, 7 Rheology Modifiers, 6 Film Formers & Plasticizers, 3 Parenteral, 3 Taste Masking, 3 Solubilizers, 3 Topical, 3 Emulsifying Agents, 2 API Stability Enhancers, 2 Coloring Agents, 2 Chewable & Orodispersible Aids, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

12 News #PharmaBuzz

12 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 1 Annual Reports

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

82 US Patents, 4 Health Canada Patents

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/03/2025	Apotex Pharmachem	Canada	APOTEX PHARMACHEM INDIA PVT LTD	27201	SAXAGLIPTIN HCI WITH MANNITOL COPRECIPITATE 20%	2013-07-05	Inactive	II	N/A
28/03/2025	Beijing Huikang Boyuan Chemical Tech	China	BEIJING HUIKANG BOYUAN CHEMICAL TECH CO LTD	29299	SAXAGLIPTIN HCL	2015-05-11	Active	II	N/A

ONGLYZA

ONGLYZA

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

20 API Suppliers

12 USDMF

8 EU WC

6 NDC API

5 Listed Suppliers

$ API Reference Price

INTERMEDIATES

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

41 FDF Dossiers

30 FDA Orange Book

2 Europe

9 Canada

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

1 SPI Pharma

5 DKSH

3 Faran Shimi Pharmaceutical

4 Gangwal Healthcare

2 Nanjing Well Pharmaceutical

1 Aeon Procare

5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 BASF

1 Clariant

5 Corel Pharma Chem

6 DFE Pharma

7 Gangwal Chemicals

3 Ideal Cures Pvt Ltd

1 Ingredion Pharma Solutions

26 Kerry

1 Kima Chemical

13 Microlex e.U

1 Novo Excipients

1 Pharmatrans-Sanaq

3 Pluviaendo

3 Prachin Chemical

10 Roquette

3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

11 Sigachi Industries

1 The Dow Chemical Company

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

45 Fillers, Diluents & Binders

23 Coating Systems & Additives

17 Thickeners and Stabilizers

15 Disintegrants & Superdisintegrants

14 Direct Compression

12 Lubricants & Glidants

11 Granulation

8 Co-Processed Excipients

8 Controlled & Modified Release

7 Rheology Modifiers

6 Film Formers & Plasticizers

3 Parenteral

3 Taste Masking

3 Solubilizers

3 Topical

3 Emulsifying Agents

2 API Stability Enhancers

2 Coloring Agents

2 Chewable & Orodispersible Aids

1 Surfactant & Foaming Agents

DIGITAL CONTENT

12 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

1 Annual Reports

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 2.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons